在转移性前列腺癌途径中嵌入基因测试:了解患者和医生的观点
Ruhee Jain1, Amanda Ribbands2, Jake Butcher2
1Market Access, Johnson & Johnson, Raritan, NJ, USA.
Future oncology (London, England)
|October 31, 2025
概括
在PARPi批准后,前列腺癌 (PCa) 的基因测试增加,医生更有可能进行测试. 挑战包括患者拒绝,成本和延迟,但测试有助于患者了解结果.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 临床实践 临床实践
背景情况:
- 聚氨酸二酸二糖聚合酶抑制剂 (PARPi) 已被批准用于转移性前列腺癌 (mPCa).
- 基因检测,包括同源重组修复 (HRR) 和乳腺癌 (BRCA) 基因,对于PARPi资格至关重要.
- 了解基因测试在临床实践中的整合和挑战至关重要.
研究的目的:
- 评估目前对mPCa.患者HRR和BRCA突变的基因测试的情况.
- 确定影响遗传检测实践的障碍和促进因素.
- 评估PARPi可用性对测试决策的影响.
主要方法:
- 从2020年和2022-2023年进行的两个阿德尔菲真实世界前列腺癌疾病特定计划TM (DSPs) 的数据分析.
- 两个DSP之间的基因测试率和突变流行率的比较.
- 两变量统计测试以评估变化和关联的意义.
主要成果:
- 在45%的mPCa患者中进行了基因检测 (HRR:43%,BRCA:42%),从2020年开始显著增加.
- 在16%的受试者中发现了HRR基因突变,15%的受试者发现了BRCA突变.
- 医生更有可能在PARPi可用性 (56%) 之后进行测试,但成本和延迟等挑战仍然存在.
结论:
- 对mPCa的基因测试增加了,受到PARPi可用性的影响.
- 医生和患者参与基因测试讨论,提高了对结果的理解和理解.
- 解决基因测试方面的挑战对于前列腺癌的最佳临床管理至关重要.
相关概念视频
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...